Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Mr. Diogo  Rau

EVice President & Chief Information and Digital Officer

Mr. Jacob S. Van Naarden

Executive Vice President & President of Loxo

Dr. Daniel M. Skovronsky M.D., Ph.D.

EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology

Ms. Anat  Hakim J.D.

Executive Vice President, General Counsel & Secretary

Mr. Alonzo  Weems

EVice President of Enterprise Risk Management and Chief Ethics & Compliance Officer

Nome	Titolo
Mr. Diogo Rau	EVice President & Chief Information and Digital Officer
Mr. Jacob S. Van Naarden	Executive Vice President & President of Loxo
Dr. Daniel M. Skovronsky M.D., Ph.D.	EVice President, Chief Scientific Officer and President of Lilly Research Laboratories & Lilly immunology
Ms. Anat Hakim J.D.	Executive Vice President, General Counsel & Secretary
Mr. Alonzo Weems	EVice President of Enterprise Risk Management and Chief Ethics & Compliance Officer
Mr. Jeffrey N. Simmons	Senior Vice President & President of Elanco Animal Health
Mr. David A. Ricks	Chairman, Chief Executive Officer & President
Mr. Eric Dozier	Executive Vice President of Human Resources & Diversity
Mr. Donald A. Zakrowski	Senior Vice President of Finance & Chief Accounting Officer
Ms. Anat Ashkenazi	Executive Vice President & Chief Financial Officer

Eli Lilly and Company

Eli Lilly and Company Struttura manageriale

Informazioni sul management